Andrija Vidic, DO
Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1003120692
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,605 of the $18,278 with a category attached, or 69.0%. 23 manufacturers reported payments, led by Abbott at 36.0% of the total. Reporting peaked in 2024 at $9,543 and has fallen 56.3% since, to $4,174 in 2025.
Across 199 payments — averaging $91.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Abiomed$5K
- Cvrx, Inc.$2K
- Medtronic$2K
- Paragonix Technologies, Inc.$966
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$569
- plus $1K from 17 others
Across 48 payments — averaging $8983.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$245K
- Paragonix Technologies, Inc.$110K
- Novartis$40K
- Briohealth Solutions, Inc.$36K
What the payments were for
- Speaking & faculty fees$3,60020%
- Travel & lodging$2,07411%
- Food & beverage$12,60569%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 88 | $6,587 |
| Abiomed | 12 | $4,685 |
| Cvrx, Inc. | 25 | $2,477 |
| Medtronic(2 entities) | 14 | $1,676 |
| Paragonix Technologies, Inc. | 10 | $966 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $569 |
| Impulse Dynamics (USA) Inc. | 3 | $212 |
| Briohealth Solutions, Inc. | 1 | $140 |
| Boston Scientific | 1 | $139 |
| Pfizer | 6 | $124 |
| Eurofins Viracor, LLC | 1 | $107 |
| Novo Nordisk | 5 | $102 |
| Boehringer Ingelheim | 2 | $101 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| Merck | 4 | $65 |
| Kestra Medical Technology Services, Inc. | 2 | $61 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Endotronix, Inc. | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Bayer | 1 | $23 |
| One Lambda, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$4,413
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,742
- Barostim Neo System$1,947
- Paragonix SherpaPak Cardiac Transport System$1,179
- SherpaCool Box$595
- LUNGguard$548
- CARDIOMEMS$424
- CTS Canister Box$357
- OPTIMIZER$347
- Shipper Box$239
- HeartMate Touch$161
- BRIOVAD$140
- WATCHMAN Access System$139
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$134
- HeartMate$124
- LifeVest$112
- HeartWare HVAD$110
How this compares
$18,278 in reported general payments places this provider in the 65th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 72 | $80,055 |
| JardianceEmpagliflozin | 85 | $78,854 |
| EliquisApixaban | 71 | $72,778 |
| FarxigaDapagliflozin Propanediol | 49 | $52,867 |
| OzempicSemaglutide | 15 | $18,263 |
| Tacrolimus | 24 | $4,903 |
| Eplerenone | 30 | $3,307 |
| Metoprolol Succinate | 78 | $1,423 |
| Bumetanide | 53 | $1,388 |
| Spironolactone | 143 | $1,355 |
| Torsemide | 31 | $1,313 |
| Potassium Chloride | 51 | $1,287 |
| Mycophenolate Mofetil | 14 | $1,159 |
| Carvedilol | 94 | $890 |
| Atorvastatin Calcium | 52 | $675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $101 | $78,85485 claims |
| PfizerEliquis | $124 | $72,77871 claims |
| AstraZenecaFarxiga | $19 | $52,86749 claims |
| Novo NordiskOzempic | $102 | $18,26315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Orlando
- Naveen BellamOrlando$414K
- Stacy MandrasOrlando$100K
- Pujan PatelOrlando$66K
- Shahid QamarOrlando$9K
- Jacqueline DoweOrlando$7K
- Sushma KoneruOrlando$7K
- Mauricio VelezOrlando$6K
- Akanksha AgrawalOrlando$5K
- Krithika KrishnaraoOrlando$4K
- Maria DemoriOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.